Quarterly ResultApr 29, 2026, 06:32 AM
REGN Q1 Revenue +19% to $3.6B; Otarmeni FDA Approved; $3B Buyback
AI Summary
Regeneron Pharmaceuticals reported strong first quarter 2026 financial results, with total revenues increasing 19% to $3.6 billion and non-GAAP diluted EPS rising 15% to $9.47. The company also announced several key regulatory approvals, including FDA approval for Otarmeni as the first gene therapy for genetic hearing loss, extended dosing for EYLEA HD, and new Dupixent indications. Additionally, Regeneron authorized a new $3.0 billion share repurchase program and entered into an agreement with the U.S. government regarding drug pricing.
Key Highlights
- FDA approved Otarmeni as the first gene therapy for genetic hearing loss.
- EYLEA HD FDA approved for dosing intervals up to 5 months for wAMD and DME.
- Dupixent FDA and EC approved for young children with CSU and FDA for AFRS.
- New $3.0 billion share repurchase program authorized.
- Total revenues increased 19% to $3.6 billion in Q1 2026.
- Non-GAAP diluted EPS rose 15% to $9.47 in Q1 2026.
- Dupixent global net sales (recorded by Sanofi) increased 33% to $4.9 billion.
- Total EYLEA HD and EYLEA U.S. net sales decreased 10% to $941 million.